1124 related articles for article (PubMed ID: 23702815)
1. Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
Guo M; Rong WT; Hou J; Wang DF; Lu Y; Wang Y; Yu SQ; Xu Q
Nanotechnology; 2013 Jun; 24(24):245101. PubMed ID: 23702815
[TBL] [Abstract][Full Text] [Related]
2. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
[TBL] [Abstract][Full Text] [Related]
3. Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Ahmad N; Alam MA; Ahmad R; Umar S; Jalees Ahmad F
J Microencapsul; 2018 Jun; 35(4):327-343. PubMed ID: 29873288
[TBL] [Abstract][Full Text] [Related]
4. [Transport of PLGA nanoparticles across Caco-2/HT29-MTX co-cultured cells].
Wen Z; Li G; Lin DH; Wang JT; Qin LF; Guo GP
Yao Xue Xue Bao; 2013 Dec; 48(12):1829-35. PubMed ID: 24689242
[TBL] [Abstract][Full Text] [Related]
5. N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption.
Sheng J; Han L; Qin J; Ru G; Li R; Wu L; Cui D; Yang P; He Y; Wang J
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15430-41. PubMed ID: 26111015
[TBL] [Abstract][Full Text] [Related]
6. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles.
Lee C; Seo J; Hwang HS; Thao LQ; Lee S; Lee ES; Lee EH; Choi HG; Youn YS
Biomed Pharmacother; 2016 Mar; 78():226-233. PubMed ID: 26898446
[TBL] [Abstract][Full Text] [Related]
7. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
8. TPGS2k/PLGA nanoparticles for overcoming multidrug resistance by interfering mitochondria of human alveolar adenocarcinoma cells.
Wang DF; Rong WT; Lu Y; Hou J; Qi SS; Xiao Q; Zhang J; You J; Yu SQ; Xu Q
ACS Appl Mater Interfaces; 2015 Feb; 7(7):3888-901. PubMed ID: 25644220
[TBL] [Abstract][Full Text] [Related]
9. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.
Chronopoulou L; Massimi M; Giardi MF; Cametti C; Devirgiliis LC; Dentini M; Palocci C
Colloids Surf B Biointerfaces; 2013 Mar; 103():310-7. PubMed ID: 23261553
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
12. Transient aggregation of chitosan-modified poly(d,l-lactic-co-glycolic) acid nanoparticles in the blood stream and improved lung targeting efficiency.
Lee SY; Jung E; Park JH; Park JW; Shim CK; Kim DD; Yoon IS; Cho HJ
J Colloid Interface Sci; 2016 Oct; 480():102-108. PubMed ID: 27421112
[TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms.
Xie X; Tao Q; Zou Y; Zhang F; Guo M; Wang Y; Wang H; Zhou Q; Yu S
J Agric Food Chem; 2011 Sep; 59(17):9280-9. PubMed ID: 21797282
[TBL] [Abstract][Full Text] [Related]
14. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
Jose S; Juna BC; Cinu TA; Jyoti H; Aleykutty NA
Colloids Surf B Biointerfaces; 2016 Jun; 142():307-314. PubMed ID: 26970818
[TBL] [Abstract][Full Text] [Related]
16. Development of sulfadiazine-decorated PLGA nanoparticles loaded with 5-fluorouracil and cell viability.
Guimarães PP; Oliveira SR; de Castro Rodrigues G; Gontijo SM; Lula IS; Cortés ME; Denadai ÂM; Sinisterra RD
Molecules; 2015 Jan; 20(1):879-99. PubMed ID: 25580685
[TBL] [Abstract][Full Text] [Related]
17. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system.
Zakeri-Milani P; Loveymi BD; Jelvehgari M; Valizadeh H
Colloids Surf B Biointerfaces; 2013 Mar; 103():174-81. PubMed ID: 23201735
[TBL] [Abstract][Full Text] [Related]
18. Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery.
Park JH; Lee JY; Termsarasab U; Yoon IS; Ko SH; Shim JS; Cho HJ; Kim DD
Int J Pharm; 2014 Oct; 473(1-2):426-33. PubMed ID: 25079433
[TBL] [Abstract][Full Text] [Related]
19. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation.
Wang J; Li L; Wu L; Sun B; Du Y; Sun J; Wang Y; Fu Q; Zhang P; He Z
Eur J Pharm Sci; 2017 Mar; 99():185-192. PubMed ID: 27989702
[TBL] [Abstract][Full Text] [Related]
20. Preparation and hydrolytic erosion of differently structured PLGA nanoparticles with chitosan modification.
Ma FK; Li J; Kong M; Liu Y; An Y; Chen XG
Int J Biol Macromol; 2013 Mar; 54():174-9. PubMed ID: 23262384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
